Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Alembic Pharma’s consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals

Leave a Reply

Your email address will not be published. Required fields are marked *